Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (148870)	10/2/2006 8:26:40 AM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

MRDAF Meridian Corporate Update 2006-10-02 06:00 ET - News Release VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- 10/02/06 Meridian Co., Ltd. ("Meridian" or the "Company") (OTCBB: MRDAF), an industry leader in the research, development, manufacturing and sales of integrative medical diagnostic equipment, is in final negotiations with a large US government-affiliated purchaser for the sale of multiple units of its Digital Pulse Analyzer. The Company expects to enter into a Letter of Intent with the purchaser shortly which will call for the execution of a definitive agreement for the purchase of a minimum of 8,000 units over a two year period. According to the negotiated terms, resulting revenues, not including revenues from related training and consulting services, are expected to be at least $28,000,000 USD. It is further expected that at least one-half of the resulting revenues will accrue to the Company during the current fiscal year ending December 31, 2006. The Company will provide further details on the terms of the purchase upon the execution of a Letter of Intent. More About: Digital Pulse Analyzer ("DPA") The "DPA" accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA approved device is inexpensive, non-invasive, and can provide results in minutes. The Company feels that use of the "DPA" can reduce cardiovascular disease through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry. Cardiovascular disease is the #1 killer in the United States with an estimated economic cost of approximately $298 billion. More About: Meridian Meridian is an established leader in the research/development, manufacturing, and sales of integrative medical diagnostic equipment. The company sells its products and equipment to a wide array of customers in the global health care industry. The company presently holds a total of 18 worldwide patents on its technology, and has received FDA approval, as well as other international regulatory approvals for many of its products. Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity. On Behalf of the Board of Directors, Hyeon Seong Myeong, President This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the company. Contacts: Meridian Medical Inc. Tariq Tyab 1-877-738-8119 Meridian Medical Inc. Peter Holeczek 1-877-738-8119 Website: www.MeridianMedical.ca